Cartesian Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview

Reuters
03-03
<a href="https://laohu8.com/S/RNAC">Cartesian Therapeutics</a> Inc <rnac.oq> expected to post a loss of 80 cents a share - Earnings Preview </rnac.oq>
  • Cartesian Therapeutics Inc RNAC.OQ RNAC.O is expected to show a fall in quarterly revenue when it reports results on March 5 (estimated) for the period ending December 31 2024

  • The Frederick Maryland-based company is expected to report a 98.7% decrease in revenue to $103.75 thousand from $8.27 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Cartesian Therapeutics Inc is for a loss of 80 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Cartesian Therapeutics Inc is $41.00​, above​ its last closing price of $18.84. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.78

-0.79

-1.13

Missed

-42.7

Jun. 30 2024

-0.91

-1.07

0.54

Beat

150.6

Mar. 31 2024

-0.80

-0.88

-10.50

Missed

-1,086.4​

Dec. 31 2023

-0.60

-1.05

-2.10

Missed

-100

​​Sep. 30 2023

-1.34

-1.75

-1.80

Missed

-2.9

Jun. 30 2023

-2.31

-2.40

-2.10

Beat

12.5​

Mar. 31 2023

-2.62

-2.61

-4.20

Missed

-60.7

Dec. 31 2022

-2.47

-2.19

1.20

Beat

154.9

This summary was machine generated March 3 at 13:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10